Trial Profile
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Atezolizumab; Cyclophosphamide; Fludarabine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ZUMA-6
- Sponsors Kite Pharma
- 13 Feb 2024 Number of treatment arms are increased from 1 to 4 by the addition of separate arms for 2 more cohorts in Phase 1 part and an arm for the phase 2 part.
- 31 Jan 2023 Status changed from active, no longer recruiting to completed.
- 18 Nov 2022 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.